Discover breaking news about Dynasil

Press Releases

 

January 17, 2018

Dynasil Corporation of America Enters Infrared High Efficiency and DLC Coatings Market

Newton, Mass., January 17, 2018 – Dynasil Corporation of America (NASDAQ: DYSL) today announced its subsidiaries EMF Corporation and Optometrics Corporation have completed their development of the first in a series of Infrared High Efficiency Anti-Reflective (HEAR) thin film coatings for the eight to twelve micron spectral region.

January 11, 2018

Dynasil Announces Submission of Xcede Technologies’ Application for First-in- Human Clinical Trial

Newton, MA. Jan 11, 2018 – The Xcede Patch clinical trial dossier was submitted today to the Medical Ethical Review Committee (MREC) Universitair Medisch Centrum Groningen (Netherlands), in anticipation of a first-in-human clinical trial. The clinical trial, which outlines the treatment of up to 30 patients undergoing various types of liver resection, will take place at two major liver surgery centers in The Netherlands. Subject to the MREC approvals, the Company anticipates that patients will be treated with the Xcede Patch in the Netherlands in early 2018.

August 10, 2017

Dynasil’s RMD Subsidiary Awarded $2.1 Million in Technology Development Grants by NIH and NASA

Newton, MA, August 10, 2017 –Dynasil Corporation of America (NASDAQ: DYSL) today
announced that its contract research subsidiary, RMD Inc., has received two Phase II grants
totaling $2.1 million under the National Institute of Health and NASA’s Small Business Innovation
Research (SBIR) and Small Business Technology Transfer (STTR) Programs.

August 2, 2017

Dynasil’s RMD Subsidiary Awarded $3.5 Million in Technology Development Grants by the U.S. DOE

Newton, MA, August 2, 2017 –Dynasil Corporation of America (NASDAQ: DYSL) today announced that its contract research subsidiary, RMD Inc., has received three Phase II grants totaling $3.5 million under the Department of Energy’s Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs.

April 4, 2017

Dynasil Subsidiary RMD’s Scintillator Research Launched on CASIS Orbital ATK CRS-7

Dynasil is very excited to announce that key scintillation crystal research done by its subsidiary RMD is included in the payload of CASIS Orbital ATK CRS-7 en-route to the International Space Station

February 28, 2017

Dynasil Hosts Annual Meeting

Dynasil hosted its annual meeting on February 23rd, 2017 in Watertown, MA on the campus of its RMD subsidiary. The meeting included presentations by President and CEO, Peter Sulick, President of RMD, Dr. Kanai Shah and CEO of Xcede, Dr. Linda Zuckerman.

February 13, 2017

Dynasil Corporation of America Reports First Quarter Fiscal 2017 Recognition of Deferred Tax Asset Benefit of $2.7 million

Newton, MA, February 13, 2017 – Dynasil Corporation of America (NASDAQ: DYSL), a developer and manufacturer of optics and photonics products, optical detection and analysis technology and components for the homeland security, medical and industrial markets, today announced earnings attributable to common stockholders of $2.8 million or $0.17 per common share for the first quarter of the 2017 fiscal year, largely as the result of a U.S. income tax benefit resulting from the deconsolidation for tax purposes of Xcede Technologies, Inc., the Company’s tissue sealant technology development joint venture.

February 10, 2017

Dynasil Corporation Schedules First Quarter Fiscal 2017 Financial Results Conference Call

Company to Webcast Conference Call Live at 5:00 p.m. ET on February 14

Newton, Mass., February 9, 2017 – Dynasil Corporation of America (NASDAQ: DYSL) plans to release financial results for the fiscal quarter ended December 31, 2016 on Monday, February 13 and management will host a conference call for investors and analysts the following day, February 14, 2017 at 5:00 p.m. ET.

December 21, 2016

Dynasil Reports Fiscal Year 2016 Financial Results

Newton, MA, December 21, 2016 – Dynasil Corporation of America (NASDAQ: DYSL), a developer and manufacturer of optics and photonics products, optical detection and analysis technology and components for the homeland security, medical and industrial markets, today announced net income of $0.3 million and $0.04 per common share for the fiscal year ended September 30, 2016 and the filing of its Annual Report on Form 10-K.

NIH logo

November 29, 2016

Dynasil’s RMD Awarded $1.9 Million in Technology Development Grants by The National Institute of Health

Newton, MA, November 29, 2016 – Dynasil Corporation of America (NASDAQ: DYSL) today announced that its contract research subsidiary, RMD Inc., has received three Phase I and one Phase II grants totaling $1.9 million under the National Institute of Health’s SBIR funding program.

Save & Share Cart
Stash it away! We'll save and create a unique link to your cart. You (or anyone with the link) will be able to use the link to retrieve the cart. Pretty cool but shop responsibly!
Back Save & Share Cart
We're ready! Are you? Remember, anyone who has the unique link to your cart will be able to retrieve it. So, share responsibly.
Your cart email sent successfully :)